Clinical pharmacology of a new beta-adrenoceptor blocking drug, befunolol. Cross-over comparison with propranolol on repeated administration.

Repeated doses of a new beta-adrenoceptor blocking agent, befunolol, were administered orally to adult male volunteers for a cross-over comparison with propranolol. The beta-adrenoceptor blocking activity of befunolol was greater than that of propranolol when assessed by the percentage reduction in exercise-induced tachycardia. The elimination half-life of drug was significantly prolonged on repeated administration of propranolol, but not of befunolol. The percentage reduction in exercise-induced tachycardia was highly correlated with the log plasma level of each drug. Both drugs produced a significant reduction in pre-exercise systolic and diastolic blood pressure, and significant attenuation of exercise-induced rise in systolic blood pressure.

[1]  T. Yamamoto,et al.  [In vitro studies on species differences in befunolol-metabolizing activities (author's transl)]. , 1980, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[2]  T. Walle,et al.  4‐Hydroxypropranolol and its glucuronide after single and long‐term doses of propranolol , 1980, Clinical pharmacology and therapeutics.

[3]  E. J. Mees,et al.  One and three doses of propranolol a day in hypertension , 1980, Clinical pharmacology and therapeutics.

[4]  T. Nadai,et al.  [Identification of urinary metabolites of befunolol in dog and man principally by mass spectrometry (author's transl)]. , 1979, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[5]  S. Masumoto,et al.  [The beta-adrenergic blocking and antiarrhythmic activities of metabolites of befunolol hydrochloride (author's transl)]. , 1979, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[6]  K. Kawahara,et al.  Simultaneous determination of befunolol, a beta-blocking agent, and its metabolite in human plasma by gas chromatography with electron-caputre detection. , 1979, Journal of chromatography.

[7]  K. Kawashima,et al.  Stereospecific radioimmunoassay for propranolol isomers. , 1976, The Journal of pharmacology and experimental therapeutics.

[8]  A. Zanchetti,et al.  Studies of the Absorption and Removal of Propranolol in Hypertensive Patients during Therapy , 1975, Circulation.

[9]  D. Shand,et al.  Disposition of propranolol VI. Independent variation in steady‐state circulating drug concentrations and half‐life as a result of plasma drug binding in man , 1973, Clinical pharmacology and therapeutics.

[10]  D. Shand,et al.  Disposition of propranolol V. Drug accumulation and steady‐state concentrations during chronic oral administration in man , 1973, Clinical pharmacology and therapeutics.

[11]  T. Walle,et al.  Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. , 1972, The Journal of pharmacology and experimental therapeutics.

[12]  J. Fitzgerald,et al.  Pharmacology of 4‐hydroxypropranolol, a metabolite of propranolol , 1971, British journal of pharmacology.

[13]  J. Oates,et al.  Plasma propranolol levels in adults With observations in four children , 1970, Clinical pharmacology and therapeutics.

[14]  P. Gillam,et al.  Treatment of Hypertension with Propranolol , 1969, British medical journal.

[15]  M. Berman,et al.  The routine fitting of kinetic data to models: a mathematical formalism for digital computers. , 1962, Biophysical journal.